Maroteaux-Lamy syndrome (mucopolysaccharidosis VI) presenting as familial myelopathy

International Journal of Neuroscience

Volumn 121, Issue 6, 2011, Pages 337-340

  Modi, Manish ^a   Singla, Veenu ^a   Khandelwal, Niranjan ^a   Prabhakar, S ^a   Duberkar, Dhananjay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Ligamentum flavum hypertrophy; Maroteaux Lamy syndrome; mucopolysaccharidosis VI; myelopathy

Indexed keywords

BACLOFEN; GLYCOSAMINOGLYCAN;

ADULT; ARTICLE; CASE REPORT; CERVICAL SPINE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DURA MATER; FACE MALFORMATION; HEPATOSPLENOMEGALY; HUMAN; LIGAMENTUM FLAVUM; MALE; MAROTEAUX LAMY SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; POSTERIOR LONGITUDINAL LIGAMENT; QUADRIPLEGIA; SPINAL CORD ISCHEMIA; URINE LEVEL; VERTEBRAL CANAL STENOSIS;

CERVICAL VERTEBRAE; DIAGNOSIS, DIFFERENTIAL; DURA MATER; GLYCOSAMINOGLYCANS; HUMANS; HYPERTROPHY; LIGAMENTUM FLAVUM; LONGITUDINAL LIGAMENTS; MALE; MUCOPOLYSACCHARIDOSIS VI; SPINAL CORD COMPRESSION; SPINAL CORD ISCHEMIA; SPINAL STENOSIS; SPINE; YOUNG ADULT;

EID: 79958021842     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.553754     Document Type: Article

References (11)

1. Auclair, D.,Hopwood, J. J., Brooks,D. A., Lemontt, M. J. F., & Crawley, A. C. (2003). Replacement therapy in Mucopolysaccharidosis type VI: Advantages of early onset of therapy. Molecular Genetics and Metabolism, 78, 163-174. (Pubitemid 36332018)
2. Giugliani, R., Harmatz, P., & Wraith, J. E. (2007). Management guidelines for mucopolysaccharidosis VI. Pediatrics, 120(2), 405-418. (Pubitemid 47219512)
3. Jin,W. D., Jackson, C. E., Desnick, R. J., & Schuchman, E.H. (1992). Mucopolysaccharidosis type VI: Identification of threemutations in the arylsulfatase B gene of patients with the severe and mild phenotypes provides molecular evidence for genetic heterogeneity. American Journal of Human Genetics, 50, 795-800.
4. Maroteaux, P., Leveque, B., Marie, J., & Lamy, M. (1963). A new dysostosis with urinary elimination of chondroitin sulfate B. Presse Medicale, 71, 1849-1852.
5. McGill, J. J., Inwood, A. C., Coman, D. J., Lipke, M. L., deLore, D., Swiedler, S. J., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-A sibling control study. Clinical Genetics, 77(5), 492-498.
6. Rovelli, A. M. (2008). The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: An update. Bone Marrow Transplant, 41(Suppl. 2), S87-S89. (Pubitemid 351864715)
7. Sheridan, M., Chaseling, R., & Johnston, I. H. (1992). Hydrocephalus, lumbar canal and Maroteaux-Lamy syndrome (Mucopolysaccharidosis type 6). Journal of Neurological Sciences, 36, 215-217. (Pubitemid 23140574)
8. Swiedler, S. J., Beck, M., Bajbouj, M., Giugliani, R., Schwartz, I., Harmatz, P., et al. (2005). Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). American Journal of Medical Genetics, 134, 144-150. (Pubitemid 40446209)
9. Tamaki, N., Kojima, N., Tanimoto, M., Suyama, T., & Matsumoto, S. (1987). Myelopathy due to diffuse thickening of the cervical dura motor in Maroteaux-Lamy syndrome : Report of a case. Neurosurgery, 21, 416-419. (Pubitemid 17135714)
10. Vedolin, L., Schwartz, I. V., Kolmos, M., Schuch, A., Azevedo, A. C., Vieira, T., et al. (2007). Brain MRI in mucopolysaccharidosis: Effect of aging and correlation with biochemical findings. Neurology, 69(9), 917-924. (Pubitemid 47329593)
11. Vougioukas, V. I., Berlis, A., Kopp, M. V., Korinthenberg, R., Spreer, J., & van Velthoven, V. (2001). Neurosurgical interventions in children with Maroteaux-Lamy syndrome: Case report and the review of the literature. Pediatric Neurosurgery, 35, 35-38. (Pubitemid 32722318)